Similar Papers

Paper Title
Journal
Date
Author
Characteristics of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) Patients Treated with Acalabrutinib in a Real World Setting in the United States
Kellie Ryan ... Aimee Near
Blood | VOL. 134
Kellie Ryan, et. al.Kellie Ryan ... Aimee Near
13 Nov 2019
Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
Michael Wang ... Adrian Bot
Blood | VOL. 136
Michael Wang, et. al.Michael Wang ... Adrian Bot
05 Nov 2020
Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
Warren C Fiskus ... Kapil N Bhalla
Blood | VOL. 140
Warren C Fiskus, et. al.Warren C Fiskus ... Kapil N Bhalla
15 Nov 2022
Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis
Arushi Khurana ... David J Inwards
American Journal of Hematology | VOL. 96
Arushi Khurana, et. al.Arushi Khurana ... David J Inwards
29 May 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
GATA 2 much: stemness and resistance in AML chemotherapy.
Thomas Mercher ... Marie-Laure Arcangeli
Blood | VOL. 145
Thomas Mercher, et. al.Thomas Mercher ... Marie-Laure Arcangeli
08 May 2025
Babesia not only is invasive but creates RBC inflexibility.
Ryan P Jajosky ... Sean R Stowell
Blood | VOL. 145
Ryan P Jajosky, et. al.Ryan P Jajosky ... Sean R Stowell
08 May 2025
Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589.
-
Blood | VOL. 145
--
08 May 2025
From prognostication to precision in acute myeloid leukemia.
Christopher S Hourigan
Blood | VOL. 145
Christopher S HouriganChristopher S Hourigan
08 May 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.